The patent covers a number of aspects relating to 3D printing of human tissues and organs by using stem cells and inkjet technology. The patent application concerns converting MRI and CT scans and resulting images in order to create a 3D structure of organs, to be printed in a 3D printer adapted to biological materials.
Moreover, the patent application discloses the biological structure of the tissue or organ, enabled by the use of a 3D bioprinter and bioink materials. The application also discloses the use of a proprietary software with an algorithm that analyzes the 3D structure of the tissue or organ. This analysis converts the 3D structure into two dimensional slices, a process required for 3D printing of the final structure.
Last week, Nano Dimension announced a successful proof of concept by 3D printing stem cells in collaboration with Accellta Ltd., a company headquartered in Haifa, Israel, that has developed proprietary technologies for the production of high quality stem cells, progenitors and differentiation.
About Nano Dimension Ltd.
Nano Dimension, founded in 2012, focuses on development of advanced 3D printed electronics systems and advanced additive manufacturing. Nano Dimension's unique products combine three advanced technologies: 3D inkjet, 3D software and nanomaterials. The company's primary products include the first 3D printer dedicated to printing multi-layer PCBs (printed circuit boards) and advanced nanotechnology-based conductive and dielectric inks.
In addition to the trading of the company's American Depositary Shares on NASDAQ, the company's ordinary shares are also traded on the TASE in Israel. The Bank of New York Mellon serves as the depositary for Nano Dimension.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Nano Dimension's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Nano Dimension could differ materially from those described in or implied by the statements in this press release.
In addition, we cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to us. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Nano Dimension's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on March 8, 2016, and in any subsequent filings with the SEC. Except as otherwise required by law, Nano Dimension undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT INVESTOR RELATIONS:
Hayden/ MS-IR LLC
To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/nano-dimension-files-us-patent-application-for-conversion-of-mri-and-ct-scans-for-3d-printing-of-tissues-and-organs-300278484.html
SOURCE Nano Dimension